The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines

Bone

Volumn 33, Issue 5, 2003, Pages 798-804

  Ono, Katsuhiro ^a,b   Akatsu, Takuhiko ^b   Kugai, Nobuo ^b   Pilbeam, Carol C ^a   Raisz, Lawrence G ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Cyclooxygenase 2; EP4 receptor; Mammary cancer; Osteoclast; Prostaglandin E2 (PGE2)

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL MODEL; BONE MARROW CELL; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; COCULTURE; CONFERENCE PAPER; CONTROLLED STUDY; GENE DISRUPTION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; PROSTAGLANDIN SYNTHESIS; PROTEIN FUNCTION; REGULATORY MECHANISM; RNA ANALYSIS; WILD TYPE;

EID: 0242708804     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(03)00264-3     Document Type: Conference Paper

References (39)

1. Weiss L. Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metastasis. 10:1992;191-199.
2. Guise T.A., Mundy G.R. Cancer and bone. Endoc Rev. 19:1998;18-54.
3. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer. 34:1998;240-245.
4. Galasko C.S.B. Mechanism of bone destruction in the development of skeletal metastases. Nature. 23:1976;507.
5. Hiraga T., Nakajima T., Ozawa H. Bone resorption induced by a metastatic human melanoma cell line. Bone. 16:1995;349-356.
6. Taube T., Elomaa I., Blomqvist C., Beneton M.N.C., Kanis J.A. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone. 15:1994;161-166.
7. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 20:1999;345-357.
8. 2 and leukemia inhibitory factor and supports osteoclast formation in vitro via stromal cell-dependent pathway. J Bone Miner Res. 13:1998;400-408.
9. Ono K., Akatsu T., Murakami T., Wada S., Nishikawa M., Kugai N., et al. Mouse mammary carcinoma cell line (BALB/c-MC) stimulates osteoclast formation from bone marrow cells through cell-to-cell contact. Bone. 23:1998;27-32.
10. Ono K., Akatsu T., Murakami T., Kitamura R., Yamamoto M., Shinomiya N., et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res. 17:2002;774-781.
11. Akatsu T., Takahashi N., Debari K., Morita I., Murota S., Nagata N., et al. Prostaglandins promote osteoclastlike cell formation by a mechanism involving cyclic adenosine 3′, 5′ monophosphate in mouse bone marrow cell cultures. J Bone Miner Res. 4:1989;29-35.
12. Coleman R.A., Smith W.L., Narumiya S. International union of pharmacology classification of prostanoid receptors properties, distribution, and structure of the receptors and their subtypes . Pharmacol Rev. 46:1994;205-229.
13. 2. J Endocrinol. 158:1998;R1-5. Corrigendum 159: 527; 1998.
14. Li X., Okada Y., Pilbeam C.C., Lorenzo J.A., Kennedy C.R.J., Breyer R.M., et al. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology. 141:2000;2054-2061.
15. Sakuma Y., Tanaka K., Suda M., Yasoda A., Natsui K., Tanaka I., et al. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res. 15:2000;218-227.
16. Suzawa T., Miyaura C., Inada M., Maruyama T., Sugimoto Y., Ushikubi F., et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption analysis using specific agonists for respective Eps . Endocrinology. 141:2000;1554-1559.
17. Nguyen M., Camenisch T., Snouwaert J.N., Hicks E., Coffman T.M., Anderson P.A., et al. The prostaglandin receptor EP4 triggers remodeling cardiovascular system at birth. Nature. 390:1997;78-81.
18. Okada Y., Lorenzo J.A., Freeman A.M., Tomita M., Morham S.G., Raisz L.G., et al. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest. 105:2000;823-832.
19. Takahashi N., Yamana H., Yoshiki S., Roodman G.D., Mundy G.R., Boyde A., et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in a mouse bone marrow cell culture. Endocrinology. 122:1988;1373-1382.
20. Raisz L.G., Simmons H.A. Effect of parathyroid hormone and cortisol on prostaglandin production by neonatal rat calvaria in vitro. Endocr Res. 11:1985;59-74.
21. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki N., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:1998;3597-3602.
22. Pederson L., Winding B., Foged N.T., Spelsberg T.C., Oursler M.J. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res. 59:1999;5849-5855.
23. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science. 289:2000;1508-1514.
24. Guise T.A., Yin J.J., Taylor S.D., Kumagai Y., Dallas M., Boyce B.F., et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 98:1996;1544-1549.
25. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140:1999;4451-4458.
26. Bendre M.S., Gaddy-Kurten D., Mon-Foote T., Akel N.S., Skinner R.A., Nicholas R.W., et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 62:2002;5571-5579.
27. Bennett A., McDonald M., Simpson S., Stamford I. Breast cancer, prostaglandins, and bone metastases. Lancet. 1:1975;1218-1220.
28. Bennett A., Charlier M., McDonald M., Simpson S., Stamford I., Zebro T. Prostaglandins and breast cancer. Lancet. 2:1977;624-626.
29. Jang B.C., Sanchez T., Schaefers H.J., Trifan O.C., Liu C.H., Creminon C., et al. Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase. J Biol Chem. 275:2000;39507-39515.
30. Liu C.H., Chang S.H., Narko K., Trisfan O.C., Wu M.T., Smith E., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 276:2001;18563-18569.
31. Rozic J.G., Chakraborty C., Lala P.K. Cyclooxygenase inhibitors related murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer. 93:2001;497-506.
32. Singh-Ranger G., Mokbel K. The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol. 28:2002;729-737.
33. Body J.J., Bartl R., Burckhardt P., Delmas P.D., Diel I.J., Fleisch H., et al. Current use of bisphosphonates in oncology. J Clin Oncol. 16:1998;3890-3899.
34. Diel I.J., Solomayer E.-F., Costa S.D., Gollan C., Goerner R., Wallwiener D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 339:1998;357-363.
35. Michigami T., Hiraga T., Williams P.J., Niewolna M., Nishimura R., Mundy G.R., et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat. 75:2002;249-258.
36. Saarto T., Blomqvist C., Virkkunen P., Elomaa I.I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients 5-year results of a randomized controlled trial . J Clin Oncol. 19:2001;10-17.
37. Simon L.S., Lanza F.L., Lipsky P.E., Hubbard R.C., Talwalker S., Schwartz B.D., et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor efficacy and safety in two placebo-controlled trials in osteoarthritis, and studies of gastrointestinal and platelet effects . Arthritis Rheum. 41:1998;1591-1602.
38. Ushikubi F., Segi E., Sugimoto Y., Murata T., Matsuoka T., Kobayashi T., et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature. 395:1998;281-284.
39. 2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem. 275:2000;19819-19823.